Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 61

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 61
---
 interests of Longevity’s directors, director nominees, named executive        
 officers and persons expected to become officers in the Business Combination.               |

| ● | In                                                                                           
 connection with the Business Combination, Longevity approved payment of transaction bonuses  
 to Bradford A. Zakes in the amount of $500,000 upon the Closing of the Business Combination. |

Recommendation to Stockholders of FutureTech The FutureTech Board believes that the Business Combination Proposal and the other proposals to be presented at the Special Meeting are in the best interest of FutureTech’s stockholders and unanimously recommends that its stockholders vote “FOR” the Business Combination Proposal and “FOR” all of the other proposals. The existence of financial and personal interests of one or more of FutureTech’s directors may result in a conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of FutureTech and its stockholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that stockholders vote for the proposals. In addition, FutureTech’s officers have interests in the Business Combination that may conflict with your interests as a stockholder. See the section entitled “ Proposal No. 1 — The Business Combination Proposal — Interests of FutureTech’s Directors and Executive Officers in the Business Combination” for a further discussion of these considerations. Sources and Uses of Funds for the Business Combination The following table summarizes the sources and uses for funding the Business Combination. These figures assume (i) that no public stockholders exercise their redemption rights in connection with the Business Combination, or alternatively, that all public stockholders exercise their redemption rights in connection with the Business Combination, and (ii) that FutureTech issues 9,217,200 shares of FutureTech Common Stock to the Existing Longevity Stockholders at the Closing as the Merger Consideration. If the actual facts are different from these assumptions, then the amounts and shares outstanding after the Closing will be different and those changes could be material. No Redemptions Scenario

|                                                        |     | Sources |             |
|:-------------------------------------------------------|:----|:--------|------------:|
| Cash in Trust(A)                                       |     | $       |  26,538,459 |
| Due from Sponsor                                       |     |         |     809,072 |
| Longevity Equity Rollover(B)                           |     |         | 100,000,000 |
| PIPE Investment                                        |     |         |   5,000,